about
Quantitative detection of therapeutic proteins and their metabolites in serum using antibody-coupled ProteinChip Arrays and SELDI-TOF-MS.Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans.Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease modelsGlycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokinesExploiting light chains for the scalable generation and platform purification of native human bispecific IgG.Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex.An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo.Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo.The basic residue cluster (55)KKWVR(59) in CCL5 is required for in vivo biologic function.Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis.Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis.Optimization of the Central Core of Indolinone-Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists.Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors.Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System.Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endotheliumInterference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system
P50
Q33263702-DA46D983-1D5C-49A3-891C-EC9EB27CF245Q33885243-81607F2F-7F16-442D-A55F-7C593698BD26Q34556640-FEA1B1D9-911F-4771-85C9-30847C0CBF8CQ34762409-BC83526B-03E9-4F39-A931-EFB14A091B38Q35119802-DFDA8586-DA72-4AA1-956B-9689B2650F41Q36283919-4E2A83A2-006A-40EA-928B-F60EDC59CE87Q36882279-3EB56892-5D94-4C2D-A23E-64301013455AQ38343397-1FD6436C-85C2-4025-8DA3-A248B3E3F657Q38353182-AECF6F26-DA7B-4CC9-873F-CACAA13C9CC3Q38718295-5618F1EF-F9AE-4C66-A0F9-6084EE1B1955Q38940024-96B37BB6-53A1-4D5B-8484-0CB0C3A3BC4AQ39455067-060BD85A-DBC2-4287-BB26-F9F697FB963EQ39512466-BE61A3DA-DF58-4378-84C0-9D0624174CBFQ39513938-5409529A-0A08-4E51-87DA-F46EE41DB0EDQ42152393-BB5BAAA5-0D6A-4BD7-A8FD-BBA35B97A7C1Q42366882-6CD499D4-6DEA-49B8-A1A8-CC18BEC4449AQ42726883-2E8D8E9B-CE9A-4FD7-BE8B-BB345BB24C3DQ48847115-B86A8AA5-E3FC-4DDA-809E-1BA1B0BE2A25Q53758334-E4441F44-364C-43B1-B413-AA0195726936Q54618538-519F8557-C6C9-4223-83A4-44BE0F071A13Q63915251-3B3C006C-1812-4D93-BAEB-9BC0042767BBQ80884566-03BD6582-A1CC-4141-BB5C-79D1DC7A4A15
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Zoe Johnson
@ast
Zoe Johnson
@en
Zoe Johnson
@es
Zoe Johnson
@nl
type
label
Zoe Johnson
@ast
Zoe Johnson
@en
Zoe Johnson
@es
Zoe Johnson
@nl
prefLabel
Zoe Johnson
@ast
Zoe Johnson
@en
Zoe Johnson
@es
Zoe Johnson
@nl
P106
P31
P496
0000-0002-4120-2579